Chardan analyst Matthew Barcus lowered the firm’s price target on Immunome (IMNM) to $8 from $9 but keeps a Buy rating on the shares. The company’s collaboration and option agreement with AbbVie (ABBV) not only provides external validation of the company’s discovery platform, but also provides important non-dilutive financing for the company, which ended 2022 with $20.3M in cash and cash equivalents, the analyst tells investors in a research note.
Published first on TheFly